ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,287,410 | -28.9% | 961,486 | 0.0% | 2.70% | -8.1% |
Q2 2023 | $27,123,520 | -3.4% | 961,486 | -41.1% | 2.93% | +3.7% |
Q1 2023 | $28,075,371 | -37.5% | 1,632,289 | -26.8% | 2.83% | -36.9% |
Q4 2022 | $44,940,940 | -9.9% | 2,231,427 | -3.1% | 4.48% | -6.6% |
Q3 2022 | $49,857,000 | -26.9% | 2,301,771 | -5.1% | 4.79% | -2.7% |
Q2 2022 | $68,173,000 | -39.1% | 2,426,095 | 0.0% | 4.92% | -25.7% |
Q1 2022 | $111,940,000 | -49.3% | 2,426,095 | -7.7% | 6.63% | +1.1% |
Q4 2021 | $220,944,000 | +24.4% | 2,628,409 | -1.4% | 6.56% | +46.6% |
Q3 2021 | $177,556,000 | +25.3% | 2,664,409 | 0.0% | 4.47% | +49.9% |
Q2 2021 | $141,747,000 | +22.6% | 2,664,409 | 0.0% | 2.98% | +17.6% |
Q1 2021 | $115,609,000 | -16.5% | 2,664,409 | 0.0% | 2.54% | -11.9% |
Q4 2020 | $138,389,000 | +58.9% | 2,664,409 | 0.0% | 2.88% | +34.3% |
Q3 2020 | $87,100,000 | -31.9% | 2,664,409 | 0.0% | 2.14% | -44.9% |
Q2 2020 | $127,945,000 | – | 2,664,409 | – | 3.89% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |